Four digital health companies have been selected as part of the latest round of the East Midlands Digital Health Accelerator programme.
The programme, run by the East Midlands Academic Health Science Network (EMAHSN), is designed to help companies with digital health innovations that have the potential to have a positive impact on the health and care system and wider economy.
Companies are supported to help expand their digital health technologies and innovations within the East Midlands and wider areas, with a tailored package of expert guidance, advice and support. This includes one-to-one support and coaching, masterclasses and opportunities to showcase products to NHS decision-makers and influencers.
The four companies selected are:
- Sapien Health – a remote health coaching solution that helps patients before and after surgery
- Remcare– allows for the remote collection of clinical data and communication with patients
- Unphased– Unphased’s innovation Consentify is a digital solution designed to streamline the patient participation and consent process in clinical trials. step of a clinical trial
- Memory Lane Games – ORCHA-certified apps enable families to instantly turn their memories into personalised cognitively stimulating activities, which aim to provide mental stimulation and personalised care for dementia patients and carers
Nicole McGlennon, EMAHSN managing director said: “The East Midlands Digital Health Accelerator is just one example of the support we can provide to health and care innovators.
“By working closely with industry, we are able to support the development and spread of health and care innovation and through our pipeline can support health and care partners to find the most appropriate solutions to their challenges, while also fuelling economic growth by supporting inward investment to businesses in the region.
“We have seen some excellent innovations make progress through their involvement in our accelerator and I look forward to working closely with the four new companies we have welcomed to the scheme.”